Bring it on! The FDA has approved elotuzumab (Empliciti) for use in relapsed multiple myeloma patients; the third new drug approval in three weeks! Elotuzumab was the first immunotherapy developed to fight myeloma. But unlike daratumumab, elo only works when combined with one of the established novel therapy agents in the IMiD class of drugs
I ran across this comprehensive article about the emergence of new myeloma immunotherapies on OncLive.com over the weekend. It features a who's who of myeloma experts. I'm having some technical difficulties posting the article. Remember Dr. Noopur Raje? She was kind enough to fly down to speak at this year's Pat's Myeloma Beach Party. Dr.
I just listened to one of the best and easiest to understand videos I've found, explaining how the new monoclonal antibodies (elotuzumab and daratumumab) work. My good friend and long lived myeloma survivor, Jack Aiello, is interviewing Dana-Farber's Dr. Paul Richardson on a Patient Power broadcast. It's short and to the point. Give it a
The myeloma world is all a twitter over Bristol-Myers Squibb's announcement that it will be applying for European Medicines Agency approval of the first immunotherapy, elotuzumab, for patients that have failed a single prior therapy. This would be a much broader approval than the company's FDA application here in the US. Here's the announcement part
I'm still hoping for some significant myeloma related data to emerge as the American Society of Clinical Oncology (ASCO) meetings wide down in Chicago. In the meantime, the Myeloma Beacon did a nice job reviewing several poster studies which focused on my genetic abnormality: an 11;14 translocation I developed after my first stem cell transplant.
My red blood counts crashed over the past 24 hours; it's taken me some time to adjust. Hard to say if Cytoxan, Kyprolis or the combination of the two is responsible. But I'm doing better now--and I have ten days to recover before my next therapy cycle. Looks like I missed some significant news while
OncLive.com posted a six member panel discussion about the two experimental drugs most likely to be approved next by the FDA: elotuzumab and ixazomib (MLN9708). The impressive group of panelists included doctors James R. Berenson, Sundar Jagannath, Shaji Kumar, Sagar Lonial, Keith K. Stewart and Jeffrey A. Zonder. Here's a write-up about the exchange, along
Speaking of new treatment options, here's an excerpt from an excellent summary of what I consider to be "stopgap" myeloma therapy measures until new immunotherapy technology moves front and center: Treatment Triplets Offer New Strategies in Relapsed Multiple Myeloma Anita T. Shaffer - OncLive.com Published Online: Friday, February 20, 2015 The treatment options for patients
I've very excited! Yesterday my registration materials arrived for next month's American Society of Hematology (ASH) annual meetings in San Francisco. And like clockwork, researchers and pharmaceutical companies have started issuing press releases promoting presentations featuring clinical trial results to be presented there. Here are two early examples. Keep in mind that a lot new
There are a half dozen experimental anti-myeloma drugs nearing the end of the research pipeline. Which is most likely to be approved and when? A biologic immunotherapy drug like elotuzumab or daratumumab? Millennium's new oral proteasome inhibitor, MLN9708? Although it only works well when combined with another drug like Revlimid, elotuzumab is the farthest along.
A week before Arnie Goodman passed away, I received a heartfelt email from George, a multiple myeloma survivor from Canada: I was moved by Arnie Goodman's column looking for his next treatment option. It brought to the forefront something I had been pondering over for some time. I am probably the only person in the
Normal 0 false false false EN-US X-NONE X-NONE MicrosoftInternetExplorer4 My dear friend and fellow Myeloma Beacon columnist, Dr. Arnie Goodman, was finally able to gain access to elotuzumab through the FDA's Compassionate Use provisions. But it wasn't easy! Even with the tireless help of Dana-Farber's Dr. Ken Anderson, it took almost a full year for
From what may be possible in the future to an easy way to temporarily overcome myeloma drug resistance now. Apparently adding something as simple and innocuous as an antibiotic can add four or more months of effectiveness to fading Revlimid therapy. Here's the abstract from a study published Friday in the American Journal of Hematology,
Could immunotherapy be the key to a multiple myeloma cure? One thing's for sure; new drugs like elotuzumab and daratumumab offer hope that researchers are developing new and significant ways to attack our cancer. The International Myeloma Foundation's, Dr. Brian Durie, blogs about immunotherapy in this month's edition of the IMF's Myeloma Minute. Here's an
Always nice to report on a promising development. Check-out this press release about the new rising myeloma therapy star, daratumumab, that I received last week: Genmab Announces New Study of Daratumumab in Double Refractory Myeloma Genmab Announces New Study of Daratumumab in Double Refractory Multiple Myeloma -- After initial data read-out in Part
Funny. I crisscross the country, flying here and there, speaking to myeloma support groups from coast to coast. Yet I rarely address our local group here north of Tampa. Last night I was the featured speaker. My topic; New Therapy Update: Finally some good news! I wanted to share my "good news" with the rest
Something was missing from this year's American Society of Clinical Oncology (ASCO) meetings in Chicago this year. Conspicuously absent was any news about one of the most promising anti-myeloma drugs, ARRY-520. Why? Was there a problem with ARRY-520's trial data? Absolutely not! It turns-out that decision makers at the company that is developing ARRY-520, Array
For me, one of the most frustrating part of reading abstracts and following oral presentation myeloma results at meetings like ASCO and ASH is that you are rarely comparing apples to apples. Are study subjects "heavily pretreated," "refractory," or both. And what about "relapsed?" Sometimes some of these terms are used interchangeably. Sometimes not. Let
New Andrew Schorr Patient Power video features an interview with experienced cancer care social worker, Brianna Garrison, at M.D. Anderson Cancer Center in Houston, Texas. Brianna discusses how she helps patients cut-through the clutter and focus on what's important to them. Tying-in with Danny Parker's recent Excercise and Multiple Myeloma series, Brianna discusses ways to
I have been keeping my eyes and ears open to learn as much as I can about the "hit it hard up front" treatment philosophy that's quickly evolving into the standard of care for newly diagnosed myeloma patients--especially if their genetic profile classifies them as "high risk." So I wanted to follow-up with a few